Individuals living with ITP face significant challenges with existing treatment options that extend beyond bleeding prevention. Current standard therapies, including corticosteroi ...
An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase inhibitor, targets the autoimmune pathophysiology of ITP by modulating B cells, macrophages, and reducing ...
Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback